109 related articles for article (PubMed ID: 27898323)
1. Peripheral blood nerve growth factor levels in major psychiatric disorders.
Rao S; Martínez-Cengotitabengoa M; Yao Y; Guo Z; Xu Q; Li S; Zhou X; Zhang F
J Psychiatr Res; 2017 Mar; 86():39-45. PubMed ID: 27898323
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis of peripheral blood nerve growth factor levels in patients with schizophrenia.
Qin XY; Wu HT; Cao C; Loh YP; Cheng Y
Mol Psychiatry; 2017 Sep; 22(9):1306-1312. PubMed ID: 28070123
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of nerve growth factor (NGF) in patients with major depression disorder and suicide risk.
Wiener CD; de Mello Ferreira S; Pedrotti Moreira F; Bittencourt G; de Oliveira JF; Lopez Molina M; Jansen K; de Mattos Souza LD; Rizzato Lara D; Portela LV; da Silva RA; Oses JP
J Affect Disord; 2015 Sep; 184():245-8. PubMed ID: 26118751
[TBL] [Abstract][Full Text] [Related]
4. Significantly lower nerve growth factor levels in patients with major depressive disorder than in healthy subjects: a meta-analysis and systematic review.
Chen YW; Lin PY; Tu KY; Cheng YS; Wu CK; Tseng PT
Neuropsychiatr Dis Treat; 2015; 11():925-33. PubMed ID: 25897228
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor in major depressive disorder, schizophrenia, and bipolar disorder: A network meta-analysis.
Pu J; Liu Y; Gui S; Tian L; Xu S; Song X; Zhong X; Chen Y; Chen X; Yu Y; Liu L; Zhang H; Wang H; Zhou C; Zhao L; Xie P
Psychiatry Res; 2020 Oct; 292():113319. PubMed ID: 32717712
[TBL] [Abstract][Full Text] [Related]
6. Reduced cerebrospinal fluid and plasma nerve growth factor in drug-naïve psychotic patients.
Kale A; Joshi S; Pillai A; Naphade N; Raju M; Nasrallah H; Mahadik SP
Schizophr Res; 2009 Dec; 115(2-3):209-14. PubMed ID: 19713082
[TBL] [Abstract][Full Text] [Related]
7. Reduced NGF serum levels and abnormal P300 event-related potential in first episode schizophrenia.
Xiong P; Zeng Y; Zhu Z; Tan D; Xu F; Lu J; Wan J; Ma M
Schizophr Res; 2010 Jun; 119(1-3):34-9. PubMed ID: 20303241
[TBL] [Abstract][Full Text] [Related]
8. The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia.
Xiong P; Zeng Y; Wan J; Xiaohan DH; Tan D; Lu J; Xu F; Li HY; Zhu Z; Ma M
Psychiatry Res; 2011 Aug; 189(1):72-6. PubMed ID: 21277636
[TBL] [Abstract][Full Text] [Related]
9. Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses.
Yuan N; Chen Y; Xia Y; Dai J; Liu C
Transl Psychiatry; 2019 Sep; 9(1):233. PubMed ID: 31534116
[TBL] [Abstract][Full Text] [Related]
10. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment.
Lee BH; Kim YK
Neuropsychobiology; 2009; 59(1):51-8. PubMed ID: 19270464
[TBL] [Abstract][Full Text] [Related]
11. Higher serum nerve growth factor levels are associated with major depressive disorder pathophysiology: a case-control study.
Salsabil L; Shahriar M; Islam SMA; Bhuiyan MA; Qusar MS; Islam MR
J Int Med Res; 2023 Apr; 51(4):3000605231166222. PubMed ID: 37038918
[TBL] [Abstract][Full Text] [Related]
12. Using Clinical Characteristics to Identify Which Patients With Major Depressive Disorder Have a Higher Genetic Load for Three Psychiatric Disorders.
Verduijn J; Milaneschi Y; Peyrot WJ; Hottenga JJ; Abdellaoui A; de Geus EJC; Smit JH; Breen G; Lewis CM; Boomsma DI; Beekman ATF; Penninx BWJH
Biol Psychiatry; 2017 Feb; 81(4):316-324. PubMed ID: 27576130
[TBL] [Abstract][Full Text] [Related]
13. Reduced serum nerve growth factor in patients with late-life depression.
Diniz BS; Teixeira AL; Machado-Vieira R; Talib LL; Gattaz WF; Forlenza OV
Am J Geriatr Psychiatry; 2013 May; 21(5):493-6. PubMed ID: 23570892
[TBL] [Abstract][Full Text] [Related]
14. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome.
Parikh V; Evans DR; Khan MM; Mahadik SP
Schizophr Res; 2003 Apr; 60(2-3):117-23. PubMed ID: 12591576
[TBL] [Abstract][Full Text] [Related]
15. Peripheral levels of BDNF and NGF in primary headaches.
Blandini F; Rinaldi L; Tassorelli C; Sances G; Motta M; Samuele A; Fancellu R; Nappi G; Leon A
Cephalalgia; 2006 Feb; 26(2):136-42. PubMed ID: 16426267
[TBL] [Abstract][Full Text] [Related]
16. TREM-1 and DAP12 expression in monocytes of patients with severe psychiatric disorders. EGR3, ATF3 and PU.1 as important transcription factors.
Weigelt K; Carvalho LA; Drexhage RC; Wijkhuijs A; de Wit H; van Beveren NJ; Birkenhäger TK; Bergink V; Drexhage HA
Brain Behav Immun; 2011 Aug; 25(6):1162-9. PubMed ID: 21421043
[TBL] [Abstract][Full Text] [Related]
17. Ultradian variation of nerve growth factor plasma levels in healthy and schizophrenic subjects.
Bersani G; Iannitelli A; Massoni E; Garavini A; Grilli A; Di Giannantonio M; Conti CM; Pancheri P
Int J Immunopathol Pharmacol; 2004; 17(3):367-72. PubMed ID: 15461870
[TBL] [Abstract][Full Text] [Related]
18. Exploring Serum Levels of Brain Derived Neurotrophic Factor and Nerve Growth Factor Across Glaucoma Stages.
Oddone F; Roberti G; Micera A; Busanello A; Bonini S; Quaranta L; Agnifili L; Manni G
PLoS One; 2017; 12(1):e0168565. PubMed ID: 28068360
[TBL] [Abstract][Full Text] [Related]
19. Stress, anxiety and schizophrenia and neurotrophic factors: the pioneer studies with nerve growth factor.
Gioiosa L; Iannitelli A; Aloe L
Riv Psichiatr; 2009; 44(2):88-94. PubMed ID: 20066809
[TBL] [Abstract][Full Text] [Related]
20. Measurements of C-reactive protein (CRP) and nerve-growth-factor (NGF) concentrations in serum and urine samples of dogs with neurologic disorders.
Kordass U; Carlson R; Stein VM; Tipold A
BMC Vet Res; 2016 Jan; 12():7. PubMed ID: 26746899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
